Riches on offer in biotech stocks THE biotech sector can be a morgue for investors and company chief executives, even those as charismatic as Pharmaxis's Alan Robertson, but as you'll find out, the sector can still generate unbelievable amounts of wealth. Robertson stepped down on Tuesday after a difficult period in which Pharmaxis's cystic fibrosis treatment Bronchitol was rejected by the US Food and Drug Administration in late January, which has seen its shares plummet more than 50 per cent.